Press Releases

22 Oct 2025

PExA files patent application for biomarkers enabling early detection of lung cancer

PExA AB (Spotlight: PEXA) announces that the company has filed a patent application covering protein patterns for the early detection of lung cancer, based on its proprietary non-invasive airway sampling technology. Lung cancer remains the leading cause of cancer-related death worldwide, largely because the disease is typically diagnosed too late. Earlier detection could dramatically increase the chances of…

Read more
28 Aug 2025

PExA to Exhibit at the World’s Largest Lung Cancer Congress – WCLC 2025 in Barcelona

PExA today announces that the company will participate as an exhibitor at the World Conference on Lung Cancer (WCLC) in Barcelona, September 6–9, 2025. For PExA, participating at WCLC marks an important milestone in the company’s strategic focus on lung cancer diagnostics, early detection, and treatment monitoring. WCLC is the world’s largest meeting dedicated to…

Read more
27 Aug 2025

PExA signs its first rental and data-sharing agreement in Australia

PExA AB is pleased to announce that The Prince Charles Hospital Foundation (TPCHF) in Brisbane, Australia, has signed a 12-month rental agreement for the PExA 2.1 research instrument. The agreement, which includes both rental and formalized data sharing, follows an earlier evaluation phase during which the technology was used to collect samples in lung disease…

Read more
01 Jul 2025

Karolinska Institute researchers launch pilot study using PExA technology to analyze antibody responses in the lower airways

A research team at Danderyd Hospital, led by Associate Professor Charlotte Thålin of Karolinska Institute, has initiated a pilot study using PExA’s non-invasive sampling technology. The aim is to analyze antibody responses in the lower airways – something that has previously not been possible without invasive procedures. Today’s vaccines generate a strong antibody response in…

Read more
20 May 2025

PExA files patent to enable RNA fragmentomics in exhaled air— unlocking molecular insights from the small airways

PExA AB, a Swedish life science company pioneering non-invasive lung research, has filed a patent application for a novel method that enables RNA fragmentomics analysis in exhaled air samples—a unique, non-invasive way to access molecular signals from the distal lung. Developed in collaboration with Sweden-based Precision BioAnalytics using RealSeq Biosciences’ proprietary RNA fragmentomics platform, the…

Read more

Archive

Categories